Tumor Mesenchymal Stem-Like Cell as a Prognostic Marker in Primary Glioblastoma
Table 1
Demographic and clinical characteristics of patients with pGBM.
Characteristics
tMSLCs (+) ()
tMSLCs (−) ()
value
Age (years)
0.683
Median
57.5
61.0
Range
28~85
24~80
Age, no. (%)
0.899
50 years, no. (%)
9 (19)
6 (18)
50 years, no. (%)
39 (81)
28 (82)
Gender
0.110
Male, no. (%)
33 (69)
17 (50)
Female, no. (%)
15 (31)
17 (50)
Median survival (months)
15.0
29.5
0.014
95% CI
9.6~20.4
11.9~47.1
Pathological diagnosis
pGBM
pGBM
Treatment
OP/Stupp
OP/Stupp
Extent of operation (patients)
0.471
Gross total resection (≥100%)
29 (60)
19 (56)
Subtotal resection (90% ≤, <100%)
18 (38)
12 (35)
Partial resection (<90%)
1 (2)
3 (9)
Molecular markers
IDH1
0.642
Wild type, no. (%)
39 (91)
26 (96)
Mutation, no. (%)
4 (9)
1 (4)
Missing data, no. (%)
5 (10)
7 (21)
1p19q
0.341
No codeletion, no. (%)
37 (80)
30 (91)
Median survival (months)
15.0
29.5
0.011
95% CI
8.9~21.1
9.1~50.0
Codeletion, no. (%)
9 (20)
3 (9)
Median survival (months)
12.9
9.3
0.886
95% CI
0.8~25.0
1.6~17.0
Missing data, no. (%)
2 (4)
1 (3)
MGMT promoter
0.653
Wild type, no. (%)
27 (59)
18 (53)
Median survival (months)
15.0
NA
0.122
95% CI
8.8~21.2
NA
Methylated, no. (%)
19 (41)
16 (47)
Median survival (months)
18.6
34.1
0.164
95% CI
6.2~31.0
13.6~54.6
Missing data, no. (%)
2 (4)
0 (0)
p53
0.522
IHC negative (<50%), no. (%)
23 (77)
13 (65)
Median survival (months)
13.7
NA
0.324
95% CI
9.8~17.6
NA
IHC positive (≥50%), no. (%)
7 (23)
7 (35)
Median survival (months)
18.6
NA
0.704
95% CI
9.9~27.3
NA
IHC mean ± S.D.
28.4 ± 27.0
33.9 ± 28.8
0.492
Range (%)
1.5~85
2.5~90
Missing data, no. (%)
18 (38)
14 (41)
EGFR
IHC mean ± S.D.
1.9 ± 1.1
2.3 ± 0.9
0.161
Range
0~3
0~3
Missing data, no. (%)
6 (13)
7 (21)
Ki 67
0.739
IHC negative (<10%), no. (%)
5 (11)
3 (9)
IHC positive (≥10%), no. (%)
40 (89)
31 (91)
IHC % mean ± S.D.
22.6 ± 14.1
30.1 ± 20.2
0.057
Range (%)
2~60
3~80
Missing data, no. (%)
3 (6)
0 (0)
S.D.: standard deviation; IDH: isocitrate dehydrogenase; LOH: loss of heterozygosity; OP/Stupp: operation followed by Stupp’s regimen; MGMT: O-6-methylguanine-DNA methyltransferase; EGFR: epidermal growth factor receptor; NA: not available.
